Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation
Multiple myeloma (MM) is a B-cell malignancy that is incurable for a majority of patients. B-cell maturation antigen (BCMA) is a lineage-restricted differentiation protein highly expressed in multiple myeloma cells but not in other normal tissues except normal plasma B cells. Due to the restricted e...
Main Author: | Tapan K. Bera |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/10/10/1387 |
Similar Items
-
Enhancing Antibody Exposure in the Central Nervous System: Mechanisms of Uptake, Clearance, and Strategies for Improved Brain Delivery
by: Kelly Schwinghamer, et al.
Published: (2023-10-01) -
Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience
by: Bianca Raffaelli, et al.
Published: (2023-02-01) -
Engineering death resistance in CHO cells for improved perfusion culture
by: Michael A. MacDonald, et al.
Published: (2022-12-01) -
Development of an enzyme-linked immunosorbent assay based on viral antigen capture by anti-spike glycoprotein monoclonal antibody for detecting immunoglobulin A antibodies against porcine epidemic diarrhea virus in milk
by: Rui Li, et al.
Published: (2023-02-01) -
An Anti-CD7 Antibody–Drug Conjugate Target Showing Potent Antitumor Activity for T-Lymphoblastic Leukemia (T-ALL)
by: Shiqi Wang, et al.
Published: (2024-01-01)